CEACAM7 CRISPR/Cas9 KO Plasmid (h): sc-406726
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CEACAM7 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CEACAM7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CEACAM7 Antibody (BAC2): sc-59946
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CEACAM7 CRISPR/Cas9 KO Plasmid (h) | sc-406726 | 20 µg | $397.00 |
Overview
CEACAM7 (carcinoembryonic antigen-related cell adhesion molecule 7) is a GPI-anchored member of the immunoglobulin superfamily implicated in homophilic and heterophilic cell–cell adhesion at epithelial surfaces. Through interactions that influence membrane organization and contact-dependent signaling, CEACAM7 contributes to epithelial differentiation, polarity, and barrier-associated processes within mucosal tissues. Altered CEACAM7 expression has been associated with epithelial remodeling and tumor-associated changes in adhesion and differentiation programs, making it a useful molecular node for studying mechanisms that link cell adhesion to growth control. In cancer biology and mucosal epithelial research, CEACAM7 is frequently examined alongside related CEACAM family members to understand pathway compensation and adhesion-driven phenotypes.
CEACAM7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CEACAM7 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CEACAM7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CEACAM7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CEACAM7 protein expression.
This CRISPR knockout system enables efficient generation of CEACAM7-deficient cell models for investigation of CEACAM7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CEACAM7 exon(s) critical for CEACAM7 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CEACAM7 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CEACAM7 CRISPR/Cas9 KO Plasmid (h) and CEACAM7 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CEACAM7 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CEACAM7 HDR Plasmid (h) and CEACAM7 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CEACAM7 homology arms to support homology-directed repair at defined CEACAM7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.